The market research firm released its “Pharma, Biotech & Medtech Half-Year Review 2020” which analyzed how the COVID-19 pandemic has affected the drug industry, clinical trials, FDA drug approvals and more.
The five biggest drug approvals in the first half of 2020 and their projected 2026 sales:
- Trodelvy (Immunomedics) treats breast cancer — $2.3 billion
- Nexletol (Esperion/Daiichi Sankyo) treats cholesterol and cardiovascular disease — $1.8 billion
- Zeposia (Bristol Myers Squibb) treats relapsing MS — $1.6 billion
- Palforzia (Aimmune) treats peanut allergies — $1.5 billion
- Tepezza (Horizon Therapeutics) treats thyroid eye disease — $1.4 billion
More articles on pharmacy:
Women experience adverse reactions 2x more than men due to clinical testing gender bias, study finds
US, McKesson sign distribution deal for COVID-19 vaccine
Sanofi inks $3.68B deal to buy California autoimmune drugmaker
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
